# US 2009/0221683 A1 · Combination of CXCR4 Antagonist and Morphogen to Increase Angiogenesis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0221683 A1
- Document ID: US20090221683A1
- Status: Published application
- Kind: A1
- Application number: 12/090,046
- Filed: 2006-10-18
- Published: 2009-09-03
- Earliest claimed: 2005-10-18
- Assignees: Caritas St.Elizabeth Medical Center of Boston, Inc
- Inventors: Douglas W. Losordo
- Web page: https://patentgrep.com/patent/US20090221683A1

## CPC

- A61K 38/193: {Colony stimulating factors [CSF]}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61K 38/1833: {Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II}
- A61K 38/1858: {Platelet-derived growth factor [PDGF]}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12N 5/0692: {Stem cells; Progenitor cells; Precursor cells}
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention generally provides methods for preventing, treating or reducing the severity of symptoms associated with tissue ischemia by administering a CXCR4 antagonist in combination with at least one nucleic acid encoding a morphogen or effective fragment thereof. In one embodiment, the methods include elevating peripheral blood endothelial progenitor cells (EPCs), bone marrow-derived stem cells (BMSCs), or both cell types. The invention has a wide spectrum of applications including reducing or eliminating tissue ischemia, especially tissue ischemia associated with a myocardial infarct (heart attack).

## Claims

### Claim 1

A method of preventing, treating, and/or alleviating symptoms associated with tissue ischemia, the method comprising administering to a subject in need thereof a therapeutically effective amount of (a) at least one CXCR4 antagonist and (b) at least one nucleic acid encoding at least one morphogen or an effective fragment of a morphogen, to prevent, treat, or alleviate the symptoms associated with the tissue ischemia in the subject.

### Claim at position 2

2-14. (canceled)

### Claim 15 (depends on 1)

The method of claim 1, wherein the CXCR4 antagonist has the formula:
Z-linker-Z′
or a pharmaceutically acceptable salt thereof
wherein Z is a cyclic polyamine containing 9-32 ring members of which 3-8 are nitrogen atoms, said nitrogen atoms separated from each other by at least 2 carbon atoms, and wherein said heterocycle may optionally contain additional heteroatoms besides nitrogen and/or may be fused to an additional ring system;
wherein Z′ may be embodied in a form as defined by Z above, or alternatively may be of the formula
—N(R)—(CR2)n—X (1)
wherein each R is independently H or straight, branched or cyclic alkyl (1-6C), n is 1 or 2, and X is an aromatic ring, including heteroaromatic rings, or is a mercaptan; and
wherein “linker” represents a bond, alkylene (1-6C) or may comprise aryl, fused aryl, oxygen atoms contained in an alkylene chain, or may contain keto groups or nitrogen or sulfur atoms.

### Claim 16 (depends on 15)

The method of claim 15, wherein Z and Z′ are both cyclic polyamines.

### Claim 17 (depends on 15)

The method of claim 15, wherein Z and Z′ are identical.

### Claim 18 (depends on 15)

The method of claim 15, wherein Z contains 12-24 members and contains 4 nitrogen atoms.

### Claim 19 (depends on 15)

The method of claim 15, wherein Z and Z′ are both 1,4,8,11-tetraazocyclotetradecane.

### Claim 20 (depends on 15)

The method of claim 15, wherein the linker comprises an aromatic ring bracketed by two methylene moieties.

### Claim 21 (depends on 15)

The method of claim 15, wherein the linker is 1,4-phenylene-bis-methylene.

### Claim 22 (depends on 15)

The method claim 15, wherein the CXCR4 antagonist is 1,1′-1,4-phenylene-bis-(methylene)-bis-1,4,8,11-tetraazacyclotetradecane (AMD-3100).

### Claim 23 (depends on 15)

The method of claim 15, wherein the CXCR4 antagonist is selected from the group consisting of:
N-[1,4,8,11-tetraazacyclotetradecanyl-1,4-phenylenebis(methylene)]-2-aminomethyl)pyridine;
7,7′-[1,4-phenylenebis(methylene)]bis-4,7,10,17-tetraazabicyclo-[13.3.1]heptadeca-1(17),13,15-triene;
7,7′-[1,4-phenylenebis(methylene)]bis-3,7,11,17-tetraazabicyclo[13.3.1]heptadeca-[(17),13,15-triene;
1,1′-[1,3-phenylenebis(methylene)]-bis-1,4,8,11-tetra-azacyclotetradecane;
1,1′-t-1,4-phenylenebis(methylene)]-bis-1,4,8,11-tetra-azacyclotetradecane;
1,1′-[1,4-phenylene-bis-(methylene)]-bis-1,4,7,10-tetraazacyclotetradecane;
1,1′-[1,3-phenylene-bis-(methylene)]-bis-1,4,7,10-tetraazacyclotetradecane; 11,11′-(1,2-propanediyl)bis-1,4,8,1-tetraazacyclotetradecane;
N-[4-(1,4,7-triazacyclotetra-decane)-1,4-phenylenebis(methylene)]-2-(aminomethyl)pyridine;
N-[7-(4,7,10-triazabicyclo[13.3.1]heptadeca-1(17),13,15-triene)-1,4-phenylenebis(methylene)]-2-(aminomethyl)pyridine;
N-[7-(4,7,10,17-tetraazabicyclo[13.3.1]heptadeca-1(17), 13,15-triene)-1,4-phenylenebis(methylene)]-2-(aminomethyl)pyridine; and
N-[4-[4,7,10,17-tetraazabicyclo[13.3.1]heptadeca-1(17), 13,15-triene]-1,4-phenylenebis(methylene)]-2-(aminomethyl)pyridine.

### Claim at position 12

24-26. (canceled)

### Claim 27 (depends on 1)

The method of claim 1, wherein the method further comprises the step of mobilizing in the subject an endothelial progenitor cells (EPCs) and/or a bone marrow-derived stem cells (BMSCs).

### Claim at position 14

28-35. (canceled)

### Claim 36

A method for inducing new blood vessel growth in myocardial tissue of a mammal in need of such treatment comprising administering a therapeutically effective amount of (a) at least one CXCR4 antagonist; and (b) at least one nucleic acid encoding at least one morphogen or an effective fragment of a morphogen.

### Claim 37 (depends on 36)

The method of claim 36, wherein the method further comprises selecting a patient having, suspected of having, and/or prone to ischemia and administering the nucleic to or near a heart or limb blood vessel in need of treatment.

### Claim 38

(canceled)

### Claim 39 (depends on 36)

The method of claim 36, wherein the method further comprises administering the nucleic with a stent, catheter, implementation for performing balloon angioplasty; or related device.

### Claim 40 (depends on 36)

The method of claim 36, wherein the myocardial tissue has been impacted by one of ischemia, infarction or dysfunction.

### Claim at position 20

41-44. (canceled)

### Claim 45

A pharmaceutical product for preventing, alleviating, or treating an ischemic disorder in a mammal, the product comprising (a) at least one CXCR4 antagonist; and (b) at least one nucleic acid encoding at least one morphogen, or at least one nucleic acid encoding at least an effective fragment of a morphogen, wherein each the antagonist and the nucleic acid are formulated to be physiologically acceptable to a mammal, the product further comprising means for administering the product to the mammal.

### Claim at position 22

46-47. (canceled)

### Claim 48 (depends on 45)

A kit comprising the pharmaceutical product of claim 45, the kit further comprising a pharmacologically acceptable carrier solution, and means for delivering at least the morphogen to the mammal and directions for using the kit.

### Claim at position 24

49-50. (canceled)

### Claim 51

A method for increasing production of EPCs and/or BMSCs in a subject, the method comprising administering a therapeutically effective amount of at least one of a CXCR4 antagonist and a nucleic acid encoding at least one of an N-terminal portion of human hedgehog (SHh) protein, human desert hedgehog (DHh) protein or human Indian Hedgehog (IHh) protein; the method further comprising increasing presence of the EPCs and/or the BMSCs in the subject.

### Claim 52

(canceled)

### Claim 53

A use of a composition for preparation of a medicament for preventing, treating, and/or alleviating symptoms associated with tissue ischemia, the composition comprising a therapeutically effective amount of (a) at least one CXCR4 antagonist; and (b) at least one nucleic acid encoding at least one morphogen or an effective fragment of a morphogen.

### Claim 54 (depends on 53)

The use of claim 53, wherein the composition is formulated for co-administration of the CXCR4 antagonist and the nucleic acid.

### Claim 55

(canceled)
